Skip to main content
Shanghai Shyndec Pharmaceutical Co., Ltd. logo

Shanghai Shyndec Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 600420 ISIN · CNE000001JG2 LEI · 300300YMNO1V06LPN087 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,283 across all filing types
Latest filing 2026-05-25 Notice of Dividend Amou…
Country CN China
Listing Shanghai Stock Exchange 600420

About Shanghai Shyndec Pharmaceutical Co., Ltd.

https://www.shyndec.com/

Shanghai Shyndec Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and distribution of chemical active pharmaceutical ingredients (APIs) and finished dosage forms. As a key industrial entity within the Sinopharm group, the company focuses on therapeutic areas such as anti-infectives, cardiovascular diseases, endocrine disorders, and oncology. Its extensive product portfolio includes various formulations, including solid orals and injectables. Shyndec operates multiple manufacturing facilities compliant with international Good Manufacturing Practice (GMP) standards, integrating a comprehensive supply chain from raw material synthesis to final drug preparation. The organization prioritizes technological advancement and quality control to provide pharmaceutical solutions for diverse clinical needs across global markets.

Recent filings

Filing Released Lang Actions
2025年年度权益分派实施公告
Notice of Dividend Amount Classification · 98% confidence The document is a detailed announcement regarding the company’s 2025 annual profit distribution plan, specifying per-share cash dividend, record date, ex-dividend date, payment date, tax treatments, and implementation methods. This matches the “Notice of Dividend Amount” category.
2026-05-25 Chinese
关于获得药品注册证书的公告
Regulatory Filings Classification · 85% confidence The document is a corporate announcement disclosing that the company has received a drug registration certificate from the National Medical Products Administration. It is neither a financial report nor an earnings release, board or management change notice, nor any other specific category. It is a general regulatory announcement regarding product approval. Therefore, it falls under the fallback category Regulatory Filings (RNS).
2026-05-21 Chinese
关于全资子公司原料药获得印度注册证书的公告
Regulatory Filings Classification · 85% confidence The document is a company announcement regarding a wholly‐owned subsidiary obtaining an Indian drug registration certificate. It contains no financial statements or data, nor is it a request for votes, call transcript, or other specialized filing. This is a general regulatory/compliance announcement, fitting the fallback category for miscellaneous regulatory filings (RNS).
2026-05-11 Chinese
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a "2025年年度股东会决议公告" which translates to "2025 Annual General Meeting Resolution Announcement." It details the date and location of the shareholders meeting, attendance, voting results on various proposals including the board report, dividend arrangements, director remuneration, and other corporate matters. It also includes legal witness statements confirming the legality and validity of the meeting and resolutions. The document is about the announcement of the resolutions passed at the Annual General Meeting (AGM), not the full AGM materials or presentations themselves. The document length is 4100 characters, which is relatively short and consistent with an announcement rather than a full report or presentation. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-08 Chinese
关于参加2026年上海辖区上市公司年报集体业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the company's participation in a collective performance explanation meeting for the annual report and quarterly report. It provides details about the meeting time, location, participation method, and contact information. It references the 2025 annual report and 2026 first quarter report but does not contain the reports themselves or detailed financial data. The document is short (1441 characters) and serves as a notice for an upcoming investor presentation event rather than the report or transcript itself. Therefore, it fits best as an Investor Presentation (IP) announcement or possibly a Report Publication Announcement (RPA). However, since it is about a performance explanation meeting (a form of investor presentation) and includes interaction details, the classification as Investor Presentation (IP) is most appropriate.
2026-05-08 Chinese
2025年年度股东会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2025 Annual General Meeting (AGM) of Shanghai Modern Pharmaceutical Co., Ltd. It details the legality of the AGM's convening, attendance, voting procedures, and results. The document does not contain financial statements or detailed financial performance data but focuses on the procedural and legal aspects of the AGM and the validity of the resolutions passed. This matches the description of 'Declaration of Voting Results & Voting Rights Announcements (DVA)' which covers official results from shareholder votes at any general meeting. The document length is over 5,000 characters and contains detailed voting results, not just an announcement of a report publication or a brief notice. Therefore, the correct classification is DVA with high confidence.
2026-05-08 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.